Neurocrine Biosciences Inc
NASDAQ:NBIX

Watchlist Manager
Neurocrine Biosciences Inc Logo
Neurocrine Biosciences Inc
NASDAQ:NBIX
Watchlist
Price: 155.51 USD 0.84% Market Closed
Market Cap: 15.5B USD

Neurocrine Biosciences Inc
Other Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Neurocrine Biosciences Inc
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Neurocrine Biosciences Inc
NASDAQ:NBIX
Other Current Liabilities
$2.4m
CAGR 3-Years
44%
CAGR 5-Years
-16%
CAGR 10-Years
-5%
Abbvie Inc
NYSE:ABBV
Other Current Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Other Current Liabilities
$12.3B
CAGR 3-Years
139%
CAGR 5-Years
67%
CAGR 10-Years
37%
Amgen Inc
NASDAQ:AMGN
Other Current Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Current Liabilities
$441.5m
CAGR 3-Years
27%
CAGR 5-Years
18%
CAGR 10-Years
34%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Current Liabilities
$545.6m
CAGR 3-Years
0%
CAGR 5-Years
-2%
CAGR 10-Years
13%
No Stocks Found

Neurocrine Biosciences Inc
Glance View

Neurocrine Biosciences Inc. is a biopharmaceutical company that has carved out a notable niche in the neurosciences landscape. Founded in 1992, this San Diego-based firm has dedicated itself to developing treatments for neurological and endocrine-related disorders. With a strong focus on conditions such as Parkinson's disease, tardive dyskinesia, and epilepsy, Neurocrine leverages its expertise in neuroscience to bring innovative therapies to those who need them most. The company’s flagship product, Ingrezza, primarily used to treat tardive dyskinesia, reflects their commitment to addressing complex, unmet medical needs. Successfully obtaining FDA approval not only boosted patient outcomes but also established Neurocrine as a leader in a specialized segment of the pharmaceutical industry. Neurocrine’s financial model thrives on the commercialization of its proprietary medications. By partnering strategically with other pharmaceutical giants, such as AbbVie, they can broaden their market reach and accelerate development of new treatments. The company generates revenue predominantly through product sales, royalties, and milestone payments associated with its collaborations. Their pipeline remains robust, focusing on both expanding indications for existing drugs and pioneering new treatments. Each new approval or advancement in clinical trials further solidifies their market position and offers potential for increased financial returns. Thus, Neurocrine Biosciences operates at the intersection of science and business, continuously pushing the boundaries of neurological treatment while maintaining a steady growth trajectory.

NBIX Intrinsic Value
148.75 USD
Overvaluation 4%
Intrinsic Value
Price

See Also

What is Neurocrine Biosciences Inc's Other Current Liabilities?
Other Current Liabilities
2.4m USD

Based on the financial report for Sep 30, 2025, Neurocrine Biosciences Inc's Other Current Liabilities amounts to 2.4m USD.

What is Neurocrine Biosciences Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
-5%

Over the last year, the Other Current Liabilities growth was 9%. The average annual Other Current Liabilities growth rates for Neurocrine Biosciences Inc have been 44% over the past three years , -16% over the past five years , and -5% over the past ten years .

Back to Top